Published June 8, 2020
Donald Mager, BS ’91, PharmD ’00 & PhD ’02, professor and vice-chair, pharmaceutical sciences, has been elected president of the American College of Clinical Pharmacology (ACCP) for 2020-2022.
Mager has been a member of ACCP since 2004 and was named a Fellow in 2009. In 2013, Mager was elected to the ACCP Board of Regents and currently serves as president-elect on the Executive Committee. He also served as a co-guest editor for a supplemental issue of The Journal of Clinical Pharmacology on biologics in 2015 and is on the editorial board of Clinical Pharmacology in Drug Development. He served on the 2013 Annual Meeting Program Committee, was chair of the Finance Committee from 2014-2016, served as treasurer from 2016-2018, and currently serves as chair of the Nominating Committee.
In addition to his academic appointments at the University at Buffalo, Mager is a member of the graduate faculty at Roswell Park Comprehensive Cancer Center in Buffalo, NY, and a visiting professor at Paris Descartes University. He has served on the Pharmaceutical Sciences and Clinical Pharmacology Advisory Committee to the Food and Drug Administration (FDA) and is on the editorial advisory boards of several journals. He has contributed to over 140 peer-reviewed publications.
He is a former president of the International Society of Pharmacometrics (ISoP) and a Fellow of ISoP, the American Association of Pharmaceutical Scientists (AAPS) and the American Association for the Advancement of Science (AAAS).
Mager's research focuses on identifying molecular and physiological factors that control the pharmacological properties of drugs, with a focus on anti-cancer and immunomodulatory agents.
The American College of Clinical Pharmacology is a professional society with members from academia, industry, government and clinical settings whose mission is dedication to improved health by optimizing therapeutics.